Gabriel Felipe Tosta

Adjunctive oral naltrexone for breakthrough craving in patients receiving extended-release injectable naltrexone for alcohol use disorder: Three cases

Craving is a subjective, poorly characterized phenomenon strongly associated with return to use in alcohol use disorder and remains difficult to manage. Extended-release naltrexone is a U.S. Food and Drug Administration–approved, evidence-based treatment, yet some patients experi...